Conditions: Kidney Neoplasms
Keywords: Axitinib in First & Second Line Treatment of Patients With Metastatic Renal Cell Cancer
Allocation: RANDOMIZED | Intervention model: 
Enrollment: 492
Healthy volunteers: no

Brief summary:
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Axitinib (AG-013736) intervention 2: Sorafenib
Intervention descriptions: intervention 1: axitinib will be given at a starting dose of 5 mg BID with continuous dosing intervention 2: sorafenib will be given at a dose of 400 mg BID continuous dosing

Protocol document: